3,668 results on '"Rosenberg, Steven"'
Search Results
202. Supplemental Table 1 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
203. Supplementary Figures from Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
204. Supplementary Tables from Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
205. Supplementary Table 2 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
206. Supplemental Information from Targeting of HPV-16+ Epithelial Cancer Cells by TCR Gene Engineered T Cells Directed against E6
207. Supplementary Materials and Methods from Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
208. Supplementary Table 3 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
209. Supplementary Figure 3 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
210. Supplementary Figure 1 from Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting
211. Supplementary Figure 2 from Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
212. Supplementary Figure Legend from Persistence of CTL Clones Targeting Melanocyte Differentiation Antigens Was Insufficient to Mediate Significant Melanoma Regression in Humans
213. CCR Translation for This Article from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
214. Supplementary Table 2 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
215. Supplementary Data from CD8+ Enriched “Young” Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma
216. Supplementary Figure 4 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
217. Supplementary Figure legends from A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
218. Supplemental figure 1 from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
219. Supplementary Data from Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
220. Supplementary methods and figure legends from Tumor-Reactive CD8+ T Cells in Metastatic Gastrointestinal Cancer Refractory to Chemotherapy
221. Supplementary Data from Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer Cells
222. Supplementary Figure 1 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
223. Supplementary Figure 1 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
224. Supplemental Figure Legends from Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma
225. Supplementary Tables 1-5 from Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
226. Supplementary Table 4 from Human Melanoma Metastases Demonstrate Nonstochastic Site-Specific Antigen Heterogeneity That Correlates with T-cell Infiltration
227. Supplemental Figure 1 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
228. Materials and Methods and Figures S1-S6 from T-cell Responses to TP53 “Hotspot” Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers
229. Supplementary Table 1 from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
230. Supplementary Figure 2 from Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor Regression
231. Supplemental Figure 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
232. Supplementary Tables 6-9 from Isolation of T-Cell Receptors Specifically Reactive with Mutated Tumor-Associated Antigens from Tumor-Infiltrating Lymphocytes Based on CD137 Expression
233. Supplemental Table 2 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
234. supplemental figure legend from Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma
235. Supplemental Table 3 from Characterization of an Immunogenic Mutation in a Patient with Metastatic Triple-Negative Breast Cancer
236. Supplementary Table 4 from Gene Expression Profiling using Nanostring Digital RNA Counting to Identify Potential Target Antigens for Melanoma Immunotherapy
237. Supplementary Figure Legend from Myeloid Cells Obtained from the Blood but Not from the Tumor Can Suppress T-cell Proliferation in Patients with Melanoma
238. Supplementary Figure 1 from Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
239. Supplementary Figure 1 from Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
240. Supplemental Figure Legend from LIGHT Elevation Enhances Immune Eradication of Colon Cancer Metastases
241. Data from Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice
242. Supplementary Data from Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens
243. Supplemental Figure S4 from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
244. Data from Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
245. Supplementary Methods from Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice
246. Data from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
247. Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
248. Supplementary Figure 5 from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
249. Data from A High Molecular Weight Melanoma-Associated Antigen–Specific Chimeric Antigen Receptor Redirects Lymphocytes to Target Human Melanomas
250. Data from Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.